Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
35.53
+1.80 (5.34%)
Feb 21, 2025, 4:00 PM EST - Market closed
Moderna Revenue
In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%. Moderna had revenue of $966.00M in the quarter ending December 31, 2024, a decrease of -65.64%.
Revenue (ttm)
$3.24B
Revenue Growth
-52.75%
P/S Ratio
4.22
Revenue / Employee
$577,857
Employees
5,600
Market Cap
13.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MRNA News
- 8 hours ago - Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China - Investopedia
- 8 hours ago - Moderna and Other Vaccine Stocks Climb After Coronavirus News From China - Investopedia
- 9 hours ago - 3 Biotech/Healthcare Names Under $10 I Am Buying Now - Seeking Alpha
- 3 days ago - Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges - Benzinga
- 7 days ago - Moderna, Inc.: Working Hard But Competition Is Working Harder - Seeking Alpha
- 7 days ago - Moderna (MRNA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints - Investopedia
- 7 days ago - Moderna beats on revenue but loses more than expected as it scales down manufacturing - CNBC